Low C-peptide: causes, levels and what your results mean

What a low C-peptide means depends on the glucose drawn beside it. Below are the cutoffs for each situation in ng/mL and pmol/L, when it is urgent, the causes from most to least likely and the tests that sort them.

Reviewed by LifeFrom’s medical AIPublished November 19, 2026 · 9 min read
Ask AI about this pageChatGPTClaudePerplexity
The distinctions
  1. 01
    Switched off vs used up

    A healthy pancreas switches insulin off when glucose is low or you have fasted, so C-peptide drops with it 1. A pancreas that has lost its beta cells cannot make insulin even when glucose is high. The same low number means opposite things in the two cases, and the only way to tell them apart is the glucose from the same draw: low C-peptide with low glucose is usually normal, low C-peptide with high glucose is insulin deficiency 2.

A C-peptide result only makes sense next to the glucose drawn at the same time. C-peptide (connecting peptide) is cut from proinsulin, the same molecule that becomes insulin, and released one-for-one with it, so it counts how much insulin your own pancreas is making, even in people who inject insulin 1. The same low number can be normal or a sign of insulin deficiency, and the glucose decides which. The overview of the test lives on our C-peptide page; this page reads the low result.

Which situation are you in?

  • No diabetes, a fasting or wellness panel, glucose normal or low: usually your pancreas had switched insulin off during the fast 1. A repeat after a meal, with glucose drawn at the same time, is the usual check.
  • Diabetes, on insulin: low C-peptide helps show which type you have. The usual next tests are islet antibodies (blood tests for an immune attack on the insulin-making beta cells) and a random C-peptide, meaning one taken at any time within 5 hours of a meal rather than fasting 2.
  • High glucose with no diabetes diagnosis: low C-peptide points to insulin deficiency, the way type 1 and LADA first show up. See a doctor promptly, the same day if you are vomiting, very thirsty or drowsy.
  • Ketones with vomiting, belly pain, fast deep breathing or drowsiness: go to the emergency department now, whatever the glucose.

What counts as low C-peptide

Your report flags C-peptide as low against the lab's own range, which is built from people without diabetes and differs between labs and assays 1 (see why reference ranges differ). Labcorp's fasting range, for example, is 1.1 to 4.4 ng/mL (about 360 to 1,460 pmol/L) 10; other labs set the lower limit lower. C-peptide comes in three units: 1 nmol/L equals 1,000 pmol/L, which is about 3 ng/mL 1. US labs mostly print ng/mL; the studies and UK reports that set the clinical cutoffs use pmol/L or nmol/L, so check the unit before comparing. The band that applies to you depends on whether you have diabetes, whether you take insulin, and what your glucose was at the draw.

No diabetes, fasting sample: where an example C-peptide of 0.9 ng/mL sitsng/mL

0.9 ng/mLJust below the range · about 300 pmol/L
Below the lab range, under 1.1 ng/mL (360 pmol/L)0–1.1Lab range, 1.1 to 4.4 ng/mL1.1–4.4Above the lab range, over 4.4 ng/mL4.4–6
In someone without diabetes whose glucose was normal or low, a fasting 0.9 ng/mL usually means the fast had switched insulin off; a doctor may repeat it after a meal.
Labcorp's fasting reference range 10; your lab's printed range is the one to use. The diabetes cutoffs below do not apply to this situation.

Insulin-treated diabetes: where an example random C-peptide of 0.9 ng/mL sitsng/mL

0.9 ng/mLMixed zone · about 300 pmol/L
Very low, under 0.24 ng/mL (80 pmol/L)0–0.24Severe insulin deficiency, under 0.6 ng/mL (200 pmol/L)0.24–0.6Mixed zone, 0.6 to 1.8 ng/mL (200 to 600 pmol/L)0.6–1.8Own insulin well preserved, over 1.8 ng/mL (600 pmol/L)1.8–3
A random C-peptide of 0.9 ng/mL in someone on insulin fits type 1 diabetes, MODY (an inherited form of diabetes) or long-standing type 2; islet antibodies are the usual next test.
Cutoffs from the 2021 consensus of the American Diabetes Association and the European Association for the Study of Diabetes (ADA/EASD), for a random sample (any time, not fasting) taken within 5 hours of eating, more than 3 years after diagnosis, with glucose drawn at the same time 2.
BandUS unitsSI unitsWhen this scale appliesWhat it usually meansUsual next step
Below the lab rangeUnder your lab's limit (Labcorp: 1.1 ng/mL)Under about 360 pmol/L at LabcorpFasting sample, no diabetesUsually a low glucose or a long fast at the draw, so the pancreas had switched insulin off 1Read beside the glucose from the same draw; a doctor may repeat it after a meal 1
Preserved1.8 ng/mL or more600 pmol/L or moreInsulin-treated diabetes, random sample within 5 h of eatingStrongly suggests type 2 diabetes 2Diabetes type is reviewed with your doctor
Mixed zone0.6 to 1.8 ng/mL200 to 600 pmol/LSame as aboveUsually type 1 or MODY; can be type 2 in people with a normal or low BMI or after many years 2Islet antibodies; genetic testing only if antibodies are negative 2
Severe insulin deficiencyUnder 0.6 ng/mLUnder 200 pmol/LSame as aboveFits type 1 diabetes 2Repeat if paired glucose was under 72 mg/dL (4.0 mmol/L) or you had fasted 2
Very lowUnder 0.24 ng/mLUnder 80 pmol/LSame as aboveAbsolute insulin deficiency; no repeat needed 2Type 1-style insulin care, decided with your doctor
Low fasting value on insulinUnder about 0.75 ng/mLUnder 250 pmol/LFasting sample, insulin-treated diabetesLikely type 1; glucose hard to control without insulin 1A fed sample is usually preferred 1
Switched off during a lowUnder 0.6 ng/mLUnder 200 pmol/LGlucose under 55 mg/dL (3.0 mmol/L) with symptomsThe body's own insulin has switched off, as it should; the cause of the low lies elsewhere 3Insulin and proinsulin from the same sample 3

Outside insulin-treated diabetes and a documented low glucose, no graded severity scale for low C-peptide exists. If you have no diabetes and a fasting result just under the lab range, there is no mild or moderate grade; the usual next step is a repeat after a meal.

When low C-peptide is urgent

Labs do not treat a low C-peptide as a critical value, so no one phones a doctor about it. The urgency comes from the glucose and ketones measured alongside it.

Is it really low?

Many single low results in people without diabetes come from the conditions of the draw. These are the usual reasons:

  • Low glucose or a long fast at the draw. Low glucose switches off both insulin and C-peptide 1. Without diabetes, a low fasting value beside a normal or low glucose is usually expected, and a doctor may repeat it after a meal 1. In insulin-treated diabetes, ADA and EASD say any result under 600 pmol/L (1.8 ng/mL) should be repeated as a random sample within 5 hours of eating if the paired glucose was under 72 mg/dL (4.0 mmol/L) or you may have fasted; a value under 80 pmol/L (0.24 ng/mL) needs no repeat 2. See fasting before a blood test.
  • Insulin taken before the test. In people on insulin, the injected dose lowers glucose and with it the pancreas's own output, so a fasting C-peptide reads lower than a fed one 1.
  • Drugs that hold back insulin release. Octreotide and other somatostatin analogs (used for acromegaly and some hormone-making tumors) and diazoxide (used for some low-glucose conditions) lower C-peptide by design.
  • Testing too soon after DKA. Very high glucose temporarily stuns beta cells, so ADA and EASD advise against measuring C-peptide within 2 weeks of a hyperglycemic emergency 2.
  • Sample handling. C-peptide in a serum or plain tube is stable for about 6 hours and degrades markedly by 24 hours; in an EDTA tube (the purple-top tube) it holds for at least 24 hours at room temperature 1. A delayed serum sample reads falsely low. See how to prepare for a blood test.
  • Units. 1 ng/mL is about 331 pmol/L, or 0.33 nmol/L. A pmol/L result read as ng/mL looks about 330 times too high, and an nmol/L result read as ng/mL looks about 3 times too low 1. See lab units explained.
  • Lab and assay. Many different C-peptide assays are in use and their results do not match exactly, so compare repeats from the same lab 1. See why trends beat single readings.

Weak kidneys work the other way. The kidneys clear about half of C-peptide, so poor kidney function pushes it falsely high 1; if your eGFR (the kidney filtration estimate) is low and your C-peptide is still low, your true output is likely even lower. See kidney function explained.

CalculatorGlucose converterGot your paired glucose in mmol/L? Convert it to check whether it was under 72 mg/dL (4.0 mmol/L), the line below which ADA and EASD advise repeating a low C-peptide in insulin-treated diabetes.Work it out

What causes low C-peptide

Common

  • Normal switch-off, no diabetes. A healthy pancreas cuts insulin when glucose falls 1. Clue: normal or low glucose, normal A1C, fasted or lean. Confirm with the fasting glucose from the same draw and an A1C.
  • Type 1 diabetes, at any age. The immune system destroys beta cells, and C-peptide falls by about 47% a year for roughly 7 years, then holds steady for decades 5. Clue: thirst, weight loss, often younger or lean. Confirm with islet antibodies, starting with GAD antibodies (the most common type) 2; see autoimmune antibodies explained.
  • LADA (latent autoimmune diabetes in adults). A slower autoimmune form that is 2 to 12% of adult-onset diabetes and often starts out looking like type 2 6. Clue: adult, managed without insulin at first, then tablets stop working. Confirm with GAD antibodies and a random C-peptide 6.
  • Long-standing insulin-treated type 2 diabetes. Beta-cell output can fall after many years, more often in people with a normal or low BMI 2. Clue: long duration, rising insulin needs. Confirm with a random C-peptide and glucose. More on type 2 diabetes.
How C-peptide falls after a type 1 diagnosis
% of starting level012345678910Decline stops
Illustrative curve drawn from the shape Shields and colleagues measured in 1,549 people with type 1 diabetes: a fall of about 47% a year for 7 years, then a stable phase with no further decline 5. Years since diagnosis on the x axis.

Less common

  • Pancreas damage (type 3c diabetes). Chronic pancreatitis, pancreatic cancer, pancreas surgery, cystic fibrosis and iron overload (hemochromatosis) destroy islets along with the digestive tissue, and this diabetes is often mislabelled type 2 9. Clue: past pancreatitis, heavy drinking, pale fatty stools, weight loss, or a high ferritin. Confirm with lipase, amylase, fecal elastase-1 (a stool test of how well the pancreas digests food), and ferritin with transferrin saturation if iron overload is possible 9.
  • Checkpoint-inhibitor diabetes. Anti-PD-1 and anti-PD-L1 cancer drugs set off an autoimmune attack on beta cells in about 0.9% of patients, and 42% had signs of pancreatitis around diagnosis 8. Clue: new high glucose during immunotherapy. Confirm with glucose, urine ketones and C-peptide 8.

Must not miss

  • Insulin from outside the body. Injected insulin lowers glucose and switches off the pancreas, so the pattern is low glucose, high insulin, suppressed C-peptide and low proinsulin 3. Some insulin tests miss modern insulin analogues, so injected insulin can show up as a low insulin; tell the lab if insulin is in the home. Red flag: unexplained lows in someone with access to insulin; same day. Confirm with insulin and proinsulin drawn during the low 3.
  • Non-insulin causes of low glucose. Low insulin, low C-peptide and low glucose together point away from insulin: large tumors that make IGF-2, adrenal insufficiency, liver or kidney failure, sepsis, starvation or alcohol 3. Red flag: lows with weight loss, a known tumor or collapse; same day. Confirm with cortisol, IGF-1 and insulin from the same sample 3.

Absent C-peptide at any time confirms absolute insulin requirement and the appropriateness of Type 1 diabetes management strategies regardless of apparent aetiology.Jones and Hattersley, The clinical utility of C-peptide measurement, Diabetic Medicine 2013 1

Does low C-peptide cause symptoms?

The number itself causes nothing. Symptoms come from too little insulin: being always thirsty, frequent urination, weight loss without trying, fatigue and, as it worsens, nausea, vomiting and belly pain from DKA 4. Someone without diabetes whose C-peptide is low only because they fasted has none of these.

In people already on insulin, a C-peptide under 200 pmol/L means wider glucose swings and more lows. Hope and colleagues put continuous glucose monitors on 17 people with insulin-treated type 2 diabetes and a C-peptide under 200 pmol/L, and on 17 matched people over 600 pmol/L, at a similar average glucose 7. In a separate group of 256 people with insulin-treated type 2, self-reported lows were twice as common below 200 pmol/L, and the rate of lows that caused loss of consciousness or seizure was about five times higher 7.

94% vs 41%had sustained lows at or below 72 mg/dL (4.0 mmol/L) on a glucose monitorRandom C-peptide under 200 vs over 600 pmol/L, 17 people per group with insulin-treated type 2 7

Read it with your other markers

PatternWhat it suggestsRead more
Low C-peptide, high glucoseThe pancreas cannot make enough insulin 2Diabetes
Low C-peptide, normal glucose, no diabetesUsually fasting or very insulin-sensitive; a doctor may repeat it after a meal 1Blood sugar explained
Low C-peptide, low glucose, high insulinInsulin given from outside the body 3Hypoglycemia
Low C-peptide, low glucose, low insulinOften a non-insulin cause of the low 3; an analogue insulin missed by the insulin test must be ruled outHypoglycemia
Low C-peptide, low eGFRMore meaningful than it looks, since weak kidneys push C-peptide up 1eGFR

Type 1, LADA or type 2?

ADA and EASD sort an unclear case in order: islet antibodies first, where a positive result points to autoimmune diabetes, then a random C-peptide once someone has had diabetes for more than 3 years 2. When clinics tested C-peptide routinely in people labelled type 1 for at least 3 years, 11% of those diagnosed as adults were reclassified 2. As our type 1 vs type 2 diabetes comparison puts it, the glucose number names the problem; C-peptide and antibodies name the type.

What usually happens next

  1. 1Repeat under the right conditionsA random sample within 5 hours of a meal, with glucose drawn at the same time, and not within 2 weeks of DKA 2.
  2. 2Islet antibodiesGAD antibodies first, then others such as IA-2 or ZnT8 if GAD is negative 2.
  3. 3A1C, and ketones if glucose is highA1C shows the 3-month picture; ketones check for DKA 4.
  4. 4ReferralA doctor may involve an endocrinologist when the diabetes type is unclear or C-peptide is very low. Genetic testing for MODY is considered only if antibodies are negative and C-peptide is over 200 pmol/L 2.
  5. 5Recheck only when it would change careNo fixed retest interval exists; a repeat makes sense when the answer would change treatment.

In LADA, an expert panel uses random C-peptide to guide treatment: under 300 pmol/L (about 0.9 ng/mL) calls for insulin as in type 1, 300 to 700 pmol/L is a grey zone, and over 700 pmol/L (about 2.1 ng/mL) allows a type 2-style approach with C-peptide monitoring 6. People with very low C-peptide also get less from medicines that work by pushing their own beta cells to release insulin, such as sulfonylureas and GLP-1 drugs like semaglutide 1. Your doctor makes these decisions; none of them is a reason to change medicine on your own.

Can low C-peptide go back up?

A low reading from fasting or a low glucose rises as soon as you eat; beta cells destroyed by type 1 diabetes do not come back. Type 2 sits in between.

ChangeEffect on C-peptide in humansEvidenceSource
Eating before a repeat test, with glucose above 72 mg/dLA result that was low only from fasting moves into its true bandConsensus guidelineADA/EASD 2021 2
Recovery from DKA or a very high glucoseStunned beta cells can recover over the following weeks, so testing waits at least 2 weeksConsensus guidelineADA/EASD 2021 2
Time in type 1 diabetes past about 7 yearsThe fall stops; remaining C-peptide holds steady (about +0.07% a year)Cohort, 1,549 peopleShields 2018 5
Major weight loss in type 2 of up to 6 yearsIn the DiRECT trial 46% returned to non-diabetic glucose; those who did regained their early insulin response and had had diabetes for less timeRandomized trial, metabolic study of 90 peopleTaylor 2018 11
Vitamin D, 2,000 IU a day, in newly diagnosed type 1Slowed the fall: 18.7% vs 62.5% reached undetectable fasting C-peptide by 18 months; it slowed the loss rather than restoring outputSmall randomized trial, 38 peopleGabbay 2012 12
Berberine, chromium, cinnamon, omega-3Marketed for blood sugar, but no convincing human trial shows any of them restores lost beta cells or reliably raises C-peptide; ask your doctor before adding them to diabetes medicineNo convincing trialNo supporting trial

Remission of type 2 through supervised weight loss, and what it takes, is covered on our type 1 vs type 2 diabetes page. For the general method behind any flag, see how to read any lab result. If your C-peptide came back above the range instead, read high C-peptide.

Free, no accountRead your blood testHave the full report? Read every marker on it free, C-peptide beside glucose and insulin; the file stays on your device.Read my results
Free, no accountDrop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.
Citations
  1. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine 2013;30(7):803-817.
  2. Holt RIG, DeVries JH, Hess-Fischl A, et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2021;44(11):2589-2625.
  3. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009;94(3):709-728.
  4. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care 2024;47(8):1257-1275.
  5. Shields BM, McDonald TJ, Oram R, et al. C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care 2018;41(7):1486-1492.
  6. Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel. Diabetes 2020;69(10):2037-2047.
  7. Hope SV, Knight BA, Shields BM, et al. Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia 2018;61(1):66-74.
  8. Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018;67(8):1471-1480.
  9. Hart PA, Bellin MD, Andersen DK, et al. Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer. Lancet Gastroenterol Hepatol 2016;1(3):226-237.
  10. Labcorp. C-Peptide, Serum (test 010108): reference range and specimen stability. Labcorp test menu.
  11. Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. Cell Metabolism 2018;28(4):547-556.e3.
  12. Gabbay MAL, Sato MN, Finazzo C, Duarte AJS, Dib SA. Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual beta-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 2012;166(7):601-607.

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.